Bayer Pharmaceuticals Private Limited, a active private limited company, was established on 29 July 1998 in Thane, Maharashtra, India. Engaging in animal pharmaceuticals & healthcare within the manufacturing sector, it holds CIN: U05195MH1998PTC116021. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹34.24 Cr and a paid-up capital of ₹21.32 Cr.
Formerly known as Bayer Zydus Health Care Private Limited. It upholds a compliant status. Employing 332 professional, Its leadership includes Shweta Rai (Managing Director), Sunil Prakashlal Narwani (Additional Director). Past directors included Manoj Kumar Satish Saxena, Fidahusein Yacub Merchant, Gayatri Anand Joshi. It holds no open charges and ₹7.40 Cr settled loans. Its latest AGM occurred on 10 September 2024, with the balance sheet filed on 31 March 2024. It is based at Bayer House, Central Avenue, Hiranandani Estate, Thane (West), Thane, Maharashtra, 400607.
U05195MH1998PTC116021
116021
29 July 1998
₹34.24 Cr
₹21.32 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Bayer Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shweta Rai | Managing Director | 01 Jan 2024 | Current |
| Sunil Prakashlal Narwani | Additional Director | 26 May 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 25 Sep 2017 | Past |
| Pramod Abcsdd | Director | 27 Apr 2018 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Additional Director | 24 Jun 2024 | Past |
| Pramod Abcsdd | Director | 26 Feb 2010 | Past |
| Pramod Abcsdd | Key Managerial Personnel | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Bayer Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.04% increase. The company also saw a substantial fall in profitability, with a 21.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 34.35%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Bayer Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹74,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Dec 2000 | Hdfc Bank Limited | ₹3.00 Cr | Satisfied |
| 13 Nov 2000 | Union Bank Of India | ₹4.00 Cr | Satisfied |
| 13 Nov 2000 | Union Bank Of India | ₹4.00 M | Satisfied |
Explore comprehensive loan charge details -
Bayer Pharmaceuticals has a workforce of 332 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Bayer Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bayer Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Sunil Prakashlal Narwani was appointed as a Additional Director was appointed as a Additional Director on 26 May 2025 & has been associated with this company since 6 months 1 day . was documented.
Progress on Kushbu Vijayshankar Pandey was appointed as a Company Secretary was appointed as a Company Secretary on 28 Apr 2025 & has been associated with this company since 6 months 29 days . was documented.
Bayer Pharmaceuticals Private Limited last Annual general meeting of members was held on 10 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Bayer Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was documented.
The activity Shweta Rai was appointed as a Managing Director was appointed as a Managing Director on 01 Jan 2024 & has been associated with this company since 1 year 10 months . was completed.
Progress on A charge registered on 13 Nov 2000 via Charge ID 90143114 with Union Bank Of India was fully satisfied on 26 Jul 2014. was documented.
Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025..
Sun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights to Sun Pharma to distribute Finerenone under the brand name Lyvelsa. Sun Pharma CEO emphasizes commitment to providing innovative medicines to Indian patients. .
Bayer raised the objection against Natcos brand launched under the name Regonat alleging infringement of its patent rights..
The CIN of Bayer Pharmaceuticals Private Limited is U05195MH1998PTC116021.
Bayer Pharmaceuticals Private Limited is headquartered at Bayer House, Central Avenue, Hiranandani Estate, Thane (West), Thane, Maharashtra, 400607.
Bayer Pharmaceuticals Private Limited was incorporated on 29 July 1998.
The current directors of Bayer Pharmaceuticals Private Limited are
The primary industry of Bayer Pharmaceuticals Private Limited is Manufacturing.
Bayer Pharmaceuticals Private Limited is unlisted.
The authorized capital of Bayer Pharmaceuticals Private Limited is ₹34.24 Cr, and the paid-up capital is ₹21.32 Cr.
The compliance status of Bayer Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX